Marion Mccourt Sells 1,215 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Marion Mccourt sold 1,215 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the transaction, the executive vice president directly owned 13,134 shares in the company, valued at $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marion Mccourt also recently made the following trade(s):

• On Thursday, September 3rd, Marion Mccourt sold 1,131 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $857.39, for a total transaction of $969,708.09.

Regeneron Pharmaceuticals Stock Down 1.9%

Regeneron Pharmaceuticals stock opened at $827.72 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $859.34. The stock has a market cap of $85.22 billion, a price-to-earnings ratio of 20.46, a PEG ratio of 1.65 and a beta of 0.20. The company’s 50-day moving average price is $738.29 and its two-hundred day moving average price is $720.10. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period in the prior year, the business posted $12.81 EPS. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Amundi boosted its holdings in shares of Regeneron Pharmaceuticals by 0.4% in the second quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock worth $631,983,000 after buying an additional 3,742 shares during the period. HighTower Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 9.7% during the second quarter. HighTower Advisors LLC now owns 64,650 shares of the biopharmaceutical company’s stock valued at $40,312,000 after acquiring an additional 5,725 shares during the period. Groupe la Francaise raised its holdings in shares of Regeneron Pharmaceuticals by 25.1% during the second quarter. Groupe la Francaise now owns 553 shares of the biopharmaceutical company’s stock valued at $321,000 after acquiring an additional 111 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $15,884,000. Finally, California State Teachers Retirement System lifted its position in shares of Regeneron Pharmaceuticals by 63,274.2% in the 2nd quarter. California State Teachers Retirement System now owns 97,723,683 shares of the biopharmaceutical company’s stock valued at $60,934,625,000 after acquiring an additional 97,569,482 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Recent commentary continues to view Regeneron as a potentially attractive long-term biotech investment, supported by its established commercial portfolio, development pipeline and strong financial profile. However, the comparison with Vertex reportedly gives Vertex the clearer near-term investment edge. Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
• Neutral Sentiment: Regeneron’s Phase 1/2 study combining cemiplimab with SNS-101 has been completed, providing a pipeline milestone, although no efficacy or regulatory results were released. Cemiplimab Combination Trial Completion
• Negative Sentiment: Several law firms are recruiting investors for a securities class action alleging that Regeneron and certain executives misled shareholders about the viability and risks of the Phase 3 Fianlimab-Libtayo trial, including its protocol change and failure to meet the primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The allegations have not been proven, but the litigation creates potential reputational, legal and financial risks. Regeneron Class Action Deadline Alert
• Negative Sentiment: Director Kathryn Guarini sold 400 shares for $340,000, while EVP Marion McCourt sold 2,346 shares for approximately $2.0 million. All sales were made under pre-arranged Rule 10b5-1 plans, reducing their value as discretionary bearish signals, but the transactions may weigh on sentiment near recent highs. SEC Insider Transaction Filing

Analysts Set New Price Targets

REGN has been the topic of a number of research reports. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. Piper Sandler reduced their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Finally, Cantor Fitzgerald lifted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Fourteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $800.36.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.